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Key Messages
• Between 20% and 30% of patients treated with proton pump inhibitors (PPIs) for gastro-esophageal reflux
disease (GERD) experience persistent symptoms of heartburn and/or regurgitation.
• This exploratory study assessed the pharmacodynamic effect of the prokinetic agent revexepride (a 5-HT4
receptor agonist) in patients with GERD who have persistent symptoms despite treatment with a PPI.
• Reflux events and associated characteristics were assessed by pH/impedance monitoring and disease symptoms
were assessed using electronic diaries and questionnaires.
• There were no consistent differences in primary or secondary pharmacodynamic endpoints between the group
receiving revexepride 0.5 mg three times daily and the group taking placebo.
• Overall, revexepride 0.5 mg was well-tolerated and no safety concerns were identified.
• No clear differences were seen in reflux parameters between the revexepride and placebo groups. This may
reflect the current problems of identifying patients who could potentially benefit from a prokinetic medication.
Abstract
Background Approximately, 20–30% of patients with
gastro-esophageal reflux disease (GERD) experience
persistent symptoms despite treatment with proton
pump inhibitors (PPIs). These patients may have
underlying dysmotility; therefore, targeting gastric
motor dysfunction in addition to acid inhibition
may represent a new therapeutic avenue. The aim of
this study was to assess the pharmacodynamic effect
of the prokinetic agent revexepride (a 5-HT4 receptor
agonist) in patients with GERD who have persistent
symptoms despite treatment with a PPI.Methods This
was a phase II, exploratory, multicenter, randomized,
placebo-controlled, double-blind, parallel-group study
in patients with GERD who experienced persistent
symptoms while taking a stable dose of PPIs (Clini-
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calTrials.gov identifier: NCT01370863). Patients were
randomized to either revexepride (0.5 mg, three times
daily) or matching placebo for 4 weeks. Reflux events
and associated characteristics were assessed by pH/
impedance monitoring and disease symptoms were
assessed using electronic diaries and questionnaires.
Key Results In total, 67 patients were enrolled in the
study. There were no significant differences between
study arms in the number, the mean proximal extent
or the bolus clearance times of liquid-containing
reflux events. Changes from baseline in the number
of heartburn, regurgitation, and other symptom events
were minimal for each treatment group and no clear
trends were observed. Conclusions & Inferences No
clear differences were seen in reflux parameters
between the placebo and revexepride groups.
Keywords 5-HT4 receptor agonist, gastro-esophageal
reflux disease, prokinetic, reflux esophagitis,
revexepride.
Abbreviations: AE, adverse event; BMI, body mass
index; e-diary, electronic diary; GERD, gastro-esopha-
geal reflux disease; HRQoL, health-related quality of
life; LES, lower esophageal sphincter; LS, least-squares;
PAGI-QOL, patient assessment of upper gastrointesti-
nal quality of life; PAGI-SYM, patient assessment of
upper gastrointestinal symptom severity index; PPI,
proton pump inhibitor; SAP, symptom association
probability; TEAE, treatment-emergent adverse event.
INTRODUCTION
Proton pump inhibitors (PPIs) are widely used to treat
patients with gastro-esophageal reflux disease (GERD).1
However, 20–30% of patients treated with PPIs for
GERD experience persistent symptoms of heartburn
and/or regurgitation.2 Acid exposure tends to be con-
trolled in the majority of these patients, suggesting that
their persistent symptoms may be caused by non-acidic
or weakly acidic reflux that is not suppressed by PPIs, or
by a differentmechanism such as esophageal dysmotility
or esophageal hypersensitivity.3–6 Persistent refluxmay
be facilitated by hypotensive esophageal dysmotility or
slow gastric emptying.7,8 Consequently, there is poten-
tial for prokinetic drugs to improve reflux symptoms by
augmenting esophago–gastric junction pressure, by
inhibiting transient lower esophageal sphincter (LES)
relaxations, and by enhancing esophageal motility and
gastric emptying.
Revexepride is a prokinetic 5-HT4 receptor agonist
that has been shown to accelerate gastric emptying in
animals and healthy humans (unpublished data). It
stimulates esophageal and gastrointestinal motility,
and accelerates transit by enhancing the physiological
release of acetylcholine from myenteric neurons. Ele-
vated local acetylcholine levels increase esophageal
peristalsis, accelerate gastric emptying, increase gastro-
esophageal barrier function, stimulate gastrointestinal
motility, and improve gastroduodenal coordination.9
Other 5-HT4 receptor agonists have also been shown to
have stimulating effects on esophageal motility, LES
pressure, and gastric emptying, with the potential to
improve symptoms in patients with GERD.10–14 How-
ever, these drugs have been withdrawn owing to
cardiovascular safety concerns, probably related to lack
of 5-HT4 receptor selectivity.
15
The main aim of this study was to assess the effect
of revexepride 0.5 mg on reflux parameters in patients
with GERD who had persistent typical reflux symp-
toms despite treatment with a PPI.
MATERIALS AND METHODS
Patients
Men and non-pregnant women aged 18–70 years were included in
the study if they had at least a 6-month history of reflux
symptoms (heartburn and/or regurgitation), and had been on
stable treatment with a PPI (a minimum of a labeled dose) for at
least the past 6 weeks as determined at the screening visit.
Patients were required to have heartburn and/or regurgitation, of
at least moderate severity, at a mean frequency of ≥3 days per
week during the run-in period, as assessed by twice-daily
completion of a diary. Patients also had to have at least 25
liquid-containing reflux events in 24 h at baseline pH/impedance
monitoring, performed while the patient was taking a PPI. The
criterion of at least 25 liquid-containing reflux events per 24 h is
based on this being the median value previously reported in
patients who had persistent reflux symptoms despite treatment
with a PPI.16,17 An endoscopy within the past 5 years was required
to confirm the absence of reflux esophagitis grade C or D
(according to the Los Angeles classification).18
Patients were excluded if they had a history of: long segment
(>3 cm) Barrett’s esophagus; a large (>3 cm) hiatus hernia; fundo-
plication; an endoscopic antireflux procedure; previous major
gastrointestinal surgery; a severe esophageal motility disorder
(e.g., scleroderma, achalasia, nutcracker esophagus); a structural
abnormality or disease of the gastrointestinal tract; or vomiting
more than once per week. In addition, patients were excluded if
they had a body mass index (BMI) ≥35 kg/m2. Prohibited medica-
tions were: CYP3A4 inhibitors; drugs known to prolong the QT
interval; drugs that affect gastrointestinal motility, including
opioids and prokinetic agents other than the study drug; and other
agents used to treat GERD, such as H2-receptor antagonists and
antacids. Additional exclusion criteria were: a history of cardio-
vascular disease (including prolonged QT interval based on elec-
trocardiogram at screening); thyrotoxicosis; psychiatric disease;
clinically significant abnormalities at screening (by physical
examination or in blood hematology or biochemistry tests); or
any other disease or abnormalities which, in the opinion of the
investigators, would compromise the study or the well-being of the
patient.
© 2014 The Authors.
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Patient selection was based on an automated local analysis. All
participants provided written consent before the initiation of
study-related activities, and the study was carried out in accor-
dance with local ethical and legal requirements and the Declara-
tion of Helsinki.
Trial design
This was a 4-week, phase II, exploratory, multicenter, random-
ized, placebo-controlled, double-blind, parallel-group study of
revexepride in patients who had reflux symptoms for a minimum
of 6 months that persisted despite being on a stable PPI regimen
for at least 6 weeks (ClinicalTrials.gov identifier: NCT01370863).
The objectives of the study were to determine: (i) the pharmaco-
dynamic effect of revexepride on parameters derived from pH/
multichannel intraluminal impedance monitoring (pH/imped-
ance); (ii) the effect of revexepride on reflux symptoms; and (iii)
the safety and tolerability of the drug.
The study was carried out at 14 sites across six European
countries: Belgium, France, Germany, Great Britain, The Nether-
lands, and Switzerland. After an initial screening visit, partici-
pants underwent a run-in phase of 14 days to establish their
symptom frequency and adherence to PPI treatment. For partic-
ipants who had been taking prohibited medications that were
stopped at screening, there was an additional 7-day washout
period before the run-in period.
At baseline, patients eligible for inclusion in the study were
randomized 1 : 1 to receive either revexepride 0.5 mg or placebo
to be taken three times daily for 4 weeks. The revexepride dose
corresponds well to the optimal dose derived from available
preclinical animal data (unpublished data). In addition, patients
continued on their stable PPI treatment regimen (maintained the
same dose and type of PPI during the study). PPI compliance was
verified by patients’ daily e-diary records. Revexepride was taken
30 min before breakfast, lunch, and dinner. Administration in
relation to meals is beneficial because meals provoke transient
LES relaxations, which causes most reflux episodes.19 The
randomization was generated using a central interactive web-
based/voice response system that applied a minimization algo-
rithm to ensure an approximate 1 : 1 balance between the two
study arms. Participants were allowed to take antacid rescue
medication (Rennie, Bayer, Bladel, the Netherlands) up to three
times daily, except during the pH/impedance monitoring periods.
Assessments were performed at the baseline visit and after 2 and
4 weeks of treatment. The presence of Helicobacter pylori was
assessed at baseline based on medical history. The presence and
grade of reflux esophagitis was determined by evaluation of
endoscopic reports from the 5 years before randomization or, if
unavailable, by an endoscopy.
Revexepride 0.5 mg and placebo tablets were visually indistin-
guishable and provided in identical medication boxes. Implemen-
tation of a central randomization system ensured that the double-
blind treatment was maintained.
Assessments
pH/impedancemonitoring Twenty-four-hour pH/impedance moni-
toring was performed at baseline and at day 28 while patients
were on a PPI. A single-use pH/impedance catheter (ComforTec
Z/pH or Sleuth Multichannel Intraluminal Impedance [MII]
ambulatory system, Sandhill Scientific, Highlands Ranch, CO,
USA, or Ohmega ambulatory system, Medical Measurement
Systems [MMS], Enschede, The Netherlands, depending on
the study center) was passed transnasally under topical anesthesia
and the esophageal pH electrode positioned 5 cm above the LES.
The same monitoring system and catheter were used for the
same individual at both baseline and day 28. System-specific
standard precalibration procedures were conducted accordingly.
For the duration of the two 24-h ambulatory pH/impedance
monitoring periods, each patient was instructed to eat similar
meals at regular times between the two pH/impedance assess-
ment visits, not to eat between meals, not to consume acidic
drinks or excessive amounts of alcohol- or quinine-containing
beverages, and not to lie down, except at bedtime. Participants
were instructed not to eat or drink from 22:00 hours the night
before each pH/impedance monitoring period. During both of the
pH/impedance monitoring periods, no strenuous activities were
allowed and patients were asked to record the onset of heartburn,
regurgitation, or other symptoms. These records were used to
assess symptom association with reflux events. The pH/imped-
ance measurements were analyzed by 24-h period, and by
recumbent (nocturnal) and upright (diurnal) periods, as well as
by the postprandial (defined as 4 h after eating any meal) and
postprandial breakfast (defined as 4 h after eating breakfast)
periods. In each center, investigators analyzed impedance tracings
to confirm patient’s inclusion either manually or by using
automatic analysis software. This was the standard automated
analysis available on the local pH-impedance software at each
study site. A central reader was employed to standardize the
evaluation of the pH/impedance data.
The three primary pharmacodynamic endpoints of the study,
assessed by prespecified post hoc central reading of the 24-h pH/
impedance monitoring records, were: (i) the number of liquid-
containing reflux events; (ii) the mean proximal extent of all
liquid-containing reflux events; and (iii) the mean bolus clearance
time of all liquid-containing reflux events. In addition, 24-h pH/
impedance monitoring allowed the evaluation of the following
secondary endpoints: the number and percentage of reflux events
categorized by acidity (acidic [pH <4], weakly acidic [pH 4–7], or
weakly alkaline [pH >7])20; composition of the reflux event (liquid,
mixed, or gas); proximal extent >15 cm; acid clearance time; and
impedance baseline levels.
Symptoms Frequency and severity of heartburn and regurgitation
were assessed using electronic diaries (e-diaries), which were
completed twice daily (in the morning and evening), from
screening until the final visit. In the morning, questions were
asked relating to sleep disturbances due to reflux events and to
heartburn and/or regurgitation symptoms when lying down. In
the evening, heartburn and/or reflux symptoms that were expe-
rienced throughout the day were assessed. In addition, patients
were asked about their drug intake (investigational product and
PPI use) to estimate exposure and compliance.
Symptoms and health-related quality of life (HRQoL) were also
evaluated at baseline, week 2, and week 4 using the Patient
Assessment of Upper Gastrointestinal Symptom Severity index
(PAGI-SYM) and Patient Assessment of Upper Gastrointestinal
Quality of Life (PAGI-QOL) questionnaires, both of which have a
2-week recall period. The PAGI-SYM and PAGI-QOL instruments
have shown good validity in assessing symptoms and HRQoL in
patients with upper gastrointestinal disorders.21,22 The PAGI-
SYM consists of 20 questions about heartburn/regurgitation,
fullness/early satiety, nausea/vomiting, bloating, upper abdomi-
nal pain, and lower abdominal pain; each item is graded on
a 6-point Likert scale (none, very mild, mild, moderate, severe,
very severe).21 The PAGI-QOL includes 30 items graded on
a 6-point scale, in the following domains: daily activities, diet and
food habits, psychological well-being and distress, clothing, and
relationships.22 Symptom assessments were also performed dur-
ing pH/impedance monitoring and the symptom association
© 2014 The Authors.
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probability (SAP) was estimated at baseline and at day 28. The
SAP indicates the statistical probability (by Fisher’s exact test) of
the association between symptoms and reflux episodes; a positive
association is defined as a SAP greater than 95%.
Adverse events and safety
Adverse events (AEs) were recorded from signing of the informed
consent form to the final visit. At baseline and final visit, vital
signs (blood pressure and pulse) were measured and electrocardi-
ography and clinical laboratory assessments (hematology, bio-
chemistry, and urinalysis) were performed.
Statistical methods
Safety, demographic, and other baseline patient characteristics
were reported for the safety population, which was defined as all
individuals randomized into the study who received at least one
dose of the investigational product. The pharmacodynamic
population was defined as all randomized patients who received
at least one dose of the investigational product and who had both
a baseline and a postbaseline pharmacodynamic assessment (i.e.,
24-h pH/impedance monitoring). All pharmacodynamic and
efficacy (symptoms and HRQoL) analyses were based on data
from the pharmacodynamic population. The following three
endpoints were selected as primary as these were considered to
be equally important: number of liquid-containing reflux events,
the proximal extent of these reflux events, and the bolus
clearance time of these reflux events. The intended sample size
for the study was 45 patients per treatment arm. Assuming a SD
of 25,23 and a difference of 14.9 in reflux events, this sample size
would allow detection of significant differences with a 5% level
of significance and with 80% power.24 With this sample size,
relevant effects could also be detected for the other two primary
endpoints. To have 90 patients completing this study, the aim
was to enroll 100 patients. Correction for multiplicity was not
necessary; however, if a significant difference for only one of the
three endpoints was required, a correction for multiplicity was
applied.
Baseline characteristics and exposure data were summarized
descriptively. Continuous endpoints were assessed using an
ANCOVA on the change from baseline, and included baseline value
as a covariate as well as treatment group and country as factors.
Least-squares (LS) mean changes from the models were presented.
For the PAGI-SYM and PAGI-QOL questionnaires, a change in
score of ≥1 point was considered clinically meaningful.25 Inferen-
tial statistical analyses of treatment effects were performed using
ANCOVA as described above.
RESULTS
Patient characteristics and baseline
demographics
This study was initiated in December 2010 and was
terminated early, on 23 March 2012, because of
recruitment difficulties and the findings of an interim
analysis. This analysis showed that the variability in
the number of reflux events was much larger than
assumed for determination of the study sample size.
This would have necessitated a substantial increase in
study sample size and therefore the study was termi-
nated. There were no safety concerns. Patients who
had enrolled before 23 March 2012 were given the
option to complete the study.
The patient disposition is presented in the supple-
mentary online information (Fig. S1). A total of 67
patients were randomized (34 to revexepride, 33 to
placebo) before study termination; 65 patients received
at least one dose of investigational product and were
therefore included in the safety population (34 revex-
epride, 31 placebo). One randomized patient was
withdrawn from the study before receiving a dose of
investigational product because not all of the inclusion
criteria had been met, and one was withdrawn because
of a non-treatment-emergent AE. Of the 65 patients in
the safety population, 62 completed the study. One
patient in the revexepride group discontinued the study
owing to treatment-emergent adverse events (TEAEs;
dizziness and headache), and two patients (one from
each treatment group) discontinued because they chose
not to undergo the second pH/impedance monitoring
(Fig. S1). There were 60 patients (31 revexepride, 29
placebo) included in the pharmacodynamic population.
Patient characteristics and baseline demographics
for the safety population are presented in Table 1. The
mean age was 44.8 years and just over half of
Table 1 Patient characteristics and baseline demographics (safety
population)
Characteristic
Revexepride
0.5 mg
t.i.d. (n = 34)
Placebo
(n = 31)
Total
(n = 65)
Age, years,
mean (SD)
43.8 (16.04) 45.8 (14.50) 44.8 (15.24)
Sex, n (%)
Female 19 (55.9) 17 (54.8) 36 (55.4)
BMI, kg/cm3,
mean (SD)
25.2 (3.78) 26.4 (4.36) 25.8 (4.07)
Helicobacter pylori infection*, n (%)
Yes 9 (26.5) 6 (19.4) 15 (23.1)
No 24 (70.6) 24 (77.4) 48 (73.8)
Unknown 1 (2.9) 1 (3.2) 2 (3.1)
Reflux esophagitis, n (%)
Grade A 11 (32.4) 6 (19.4) 17 (26.2)
Grade B 3 (8.8) 3 (9.7) 6 (9.2)
History of GERD
symptoms, months,
mean (SD)
128.8 (127.09) 102.7 (82.24) 116.3 (108.03)
Did PPI therapy provide relief? n (%)
Not at all 5 (14.7) 6 (19.4) 11 (16.9)
A little bit 11 (32.4) 18 (58.1) 29 (44.6)
Somewhat 10 (29.4) 5 (16.1) 15 (23.1)
Quite a bit 6 (17.6) 2 (6.5) 8 (12.3)
Very much 2 (5.9) 0 2 (3.1)
*Determination of H. pylori infection based on medical history only.
BMI, body mass index; GERD, gastro-esophageal reflux disease; PPI,
proton pump inhibitor; SD, standard deviation; t.i.d., three times daily.
© 2014 The Authors.
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participants were female (n = 36; 55.4%). Participants
had a mean duration of reflux symptoms of
116.3 months (approximately 9.7 years). Overall,
83.1% of participants stated that PPI therapy provided
at least ‘a little bit’ of relief, while 16.9% stated that it
provided no relief. In general, patient characteristics
and baseline demographics were similar in the placebo
and revexepride groups.
Investigational product
The majority of patients were exposed to investiga-
tional product for 28–30 days. Mean (SD) duration of
exposure was comparable in the revexepride (26.9 [3.1]
days) and placebo (27.7 [1.2] days) groups. The mean
(SD) number of tablets per day was 2.82 (0.30)
corresponding to a daily dose of 1.41 mg (0.15) for
patients treated with revexepride, and 2.90 (0.14)
tablets for those who received placebo, corresponding
to a mean (SD) daily dose of 1.45 (0.07) mg (based on
the e-diary).
PPI intake
During the study, the overall mean (SD) patient
duration of exposure to PPI therapy was 26.4 (2.7)
days, which was similar in both study arms (revexe-
pride 0.5 mg, 25.9 [3.24] days; placebo, 26.9 [1.7] days).
All patients took their PPI for 21–30 days. The most
common PPIs taken (each by >10% of patients) were,
in descending order, esomeprazole, omeprazole, and
pantoprazole. PPI dosage data were available from 64
patients; 41 (64%) patients received a PPI dose once
daily; 23 (36%) received PPIs more than once a day (22
patients received PPIs twice a day and one patient
received PPIs three times a day).
Primary pharmacodynamic endpoints
The mean daily number of liquid-containing reflux
events at baseline were 92.1 and 82.0 for revexepride
and placebo, respectively. The changes from baseline
to day 28 (17.6 for revexepride and 16.3 for placebo)
were not statistically significantly different (p = 0.869)
in either study arm (Fig. 1A). In addition, no statisti-
cally significant differences between study arms were
recorded for any other periods analyzed (24-h, upright,
recumbent, postprandial, and postprandial breakfast).
The mean proximal extent of liquid-containing reflux
events in a 24-h period changed very little (0.7) from
baseline to day 28 in either treatment group (Fig. 1B),
and there was no statistically significant difference
between the study arms in LS mean changes from
baseline (p = 0.992). During the recumbent period, the
LS mean change in the mean proximal extent from
baseline was +2.06 cm in the revexepride group and
0.25 cm in the placebo group; the difference in LS
mean changes was statistically significant (p = 0.020).
The mean bolus clearance time of liquid-containing
reflux events over a 24-h period at baseline and at day
28 are presented in Fig. 1C. There was no statistically
significant difference between the study arms in LS
mean changes from baseline of the average bolus
clearance times of liquid-containing reflux events over
a 24-h period; 1.77 for revexepride and 3.77 for
placebo (p = 0.715).
A
B
C
Figure 1 Changes in the primary pharmacodynamic endpoints per
24 h from baseline to day 28 in the revexepride 0.5 mg t.i.d. and
placebo groups: (A) mean (SD) number of liquid-containing reflux
events; (B) mean (SD) proximal extent of liquid-containing reflux
events; and (C) mean (SD) bolus clearance time of liquid-containing
reflux events (pharmacodynamic population). Note that differences in
the changes from baseline to day 28 between placebo and revexepride
groups were not significant. SD, standard deviation; t.i.d., three times
daily.
© 2014 The Authors.
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Secondary pharmacodynamic endpoints
pH/impedance monitoring The secondary pharmaco-
dynamic endpoints derived from pH/impedance mon-
itoring are presented in the supplementary
information (Table S1). Acid exposure at baseline
was generally within the normal range (placebo: 3.2
[95% CI: 1.17–5.24] and revexepride: 1.78 [95% CI:
0.92–2.65]). The percentage of reflux events that were
weakly acidic during the recumbent period signifi-
cantly decreased from baseline in the revexepride
treatment group (LS mean change from baseline:
10.89%) compared with the placebo group (LS mean
change: +11.82%; p = 0.023). There were no signifi-
cant differences in the changes from baseline between
study arms for acidic, weakly acidic, and weakly
alkaline reflux for the other assessment periods. There
was a significant difference between study arms for
the LS mean change from baseline in the number of
mixed composition reflux events during the postpran-
dial assessment period (revexepride, 2.08 events;
placebo, 9.35 events; p = 0.042), but not for any of
the other assessment periods. There were no signifi-
cant differences between treatment groups for liquid
or gas reflux events for any assessment period. Acid
clearance time changes from baseline and changes
from baseline in the percentage of liquid-containing
reflux events with a proximal extent greater than
15 cm were not statistically different between placebo
and revexepride for any of the assessment periods.
Differences between treatment groups in the changes
in impedance values from baseline at any of the
channels were also not statistically significant (data
not presented).
Symptom association The changes from baseline in
the percentage of patients reporting heartburn, regurgi-
tation, and other symptoms during the pH/impedance
monitoring by period are presented in the supplemen-
tary information (Table S2). No clear trends were in the
changes from baseline in the percentage of patients
reporting each symptom were observed. The change
from baseline in the percentage of patients reporting
symptoms was statistically significant in favor of
placebo for heartburn and regurgitation (p = 0.043 and
0.049, respectively) during the recumbent period, and
for other symptoms while upright (p = 0.049), and
during the postprandial period (p = 0.035). By contrast,
there was a statistically significant decrease from
baseline in the revexepride treatment group compared
with the placebo treatment group in percentage of
patients reporting regurgitation symptoms for the 24-h
(placebo, 16.4%; revexepride, 2.9%), upright (placebo,
15.3%; revexepride, 5.5%), and postprandial (placebo,
9.2%; revexepride, 9.7%) assessment periods
(p = 0.011, 0.007 and 0.027, respectively).
The average number of symptom events associated
with a reflux event when assessed over 2- and 5-min
intervals (for all pH levels) are presented in the
supplementary information (Table S3). Overall, the
changes in symptom association from baseline were
minimal and not statistically significantly different
between study arms for any symptom, time interval,
or acidity category. The differences between study
arms in the changes from baseline in the percentage
of patients with a positive SAP were also not
statistically significant for any symptom or acidity
category.
Symptom e-diaries, PAGI-SYM, and PAGI-QOL The
mean number of daily occurrences of heartburn,
regurgitation, and heartburn and/or regurgitation in
both placebo and revexepride groups during the run-in
period and in the 4-week period are presented in Fig. 2.
Analysis of the changes from run-in to the treatment
period in the number of days with and without
symptoms (as recorded by patients in twice-daily e-
diaries) is presented in Table 2. There were no statis-
tically significant differences between study arms in
the changes from run-in to week 4 in the number of
days with heartburn or regurgitation (Table 2). There
were also no statistically significant differences
between study arms in the changes from run-in to
week 4 in the percentage of days without heartburn or
regurgitation (Table 2).
The findings from both the PAGI-SYM and PAGI-
QOL questionnaires support the results documented in
the e-diaries. The mean (SD) PAGI-SYM total scores for
symptom severity were similar (very mild to mild) in
both study arms at baseline (revexepride, 1.76 [0.96];
placebo, 1.92 [0.86]) and at day 28 (revexepride, 1.39
[0.93]; placebo, 1.55 [0.96]). There was a 0.44-point LS
mean decrease in overall score from baseline to day 28
for the revexepride group, and a 0.35-point LS mean
decrease from baseline for the placebo group; the
difference between these values was not significant
(p = 0.673; ANCOVA). The mean (SD) total PAGI-QOL
scores were similar in placebo and revexepride groups
at baseline (revexepride, 3.95 [0.79]; placebo, 3.74
[0.96]) and at day 28 (revexepride, 4.09 [0.68]; placebo,
3.91 [0.88]). Mean changes from baseline in the total
scores in both study arms were minimal (≤0.21). There
were no significant differences between study arms in
the LS mean changes from baseline to day 14 or to day
28 in the PAGI-QOL total score (p = 0.708 and
p = 0.481, respectively).
© 2014 The Authors.
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Adverse events and safety
No patients experienced a serious TEAE, and most
TEAEs were mild to moderate. The proportion of
patients who experienced at least one TEAE was higher
in the revexepride group (73.5%) than in the placebo
group (51.6%; Table 3). In the revexepride group, the
TEAEs reported by the greatest numbers of patients
were transient diarrhea (38.2%), headache (35.3%),
abdominal pain (8.8%), nausea (8.8%), and nasophar-
yngitis (8.8%). One patient in the revexepride group
discontinued treatment owing to TEAEs (dizziness and
headache).
Clinical laboratory findings and vital signs (pulse
rate, blood pressure, and weight) were similar at
screening, predose on day 1, and on day 29 in both
study arms. The increase in mean heart rate from
baseline to day 29 was numerically greater in the
revexepride group (2.3  8.00 beats/min) than in the
placebo group (1.4  9.9 beats/min). The number of
patients with a numerical heart rate increase at day 29,
however, was similar in both study arms.
DISCUSSION
In this study, the pharmacodynamic effect of revexe-
pride 0.5 mg three times daily on reflux parameters
were evaluated in patients with GERD who had
persistent reflux symptoms despite PPI therapy. In
healthy volunteers, a maximum effect on gastric
emptying was obtained with a 0.5 mg dose, which
corresponds well to the optimal dose derived from
available preclinical animal data (unpublished data). In
this investigation, however, no consistent effect of
revexepride 0.5 mg on the primary or secondary phar-
macodynamic endpoints of gastro-esophageal reflux
and reflux symptoms was recorded, compared with
placebo.
For patients with persistent symptoms on PPI
therapy, the relationship between symptoms and gas-
tro-esophageal reflux, both acidic and non-acidic, can
be evaluated more thoroughly with pH/impedance
monitoring than with conventional pH monitoring.26
In this exploratory study, pH/impedance monitoring
did not reveal a clear treatment effect of revexepride on
acidic, weakly acidic, or alkaline reflux events of
mixed, liquid, or gaseous composition. A high proxi-
mal extent of reflux (≥15 cm above the LES) and mixed
gas/liquid reflux has been found to be strongly associ-
ated with the perception of clinical symptoms during
reflux episodes.27,28 No significant effect was detected
on the proximal extent or duration of reflux, and no
significant changes were observed when evaluating the
overall relationship between reflux events and symp-
toms as assessed during pH/impedance monitoring,
although revexepride did reduce the number of regur-
gitation events more than placebo during pH/imped-
ance monitoring.
Regurgitation can be caused by esophageal dysmo-
tility and volume reflux.27,29,30 In previous studies, a
reduction in regurgitation has been attributed to the
prokinetic effects of 5-HT4 receptor agonists such as
cisapride and tegaserod on esophageal function,11,13
supporting the proposal that prokinetic agents can be
complementary to PPIs in regurgitation-predominant
patients.31 However, in the present study, while rev-
exepride had an effect on regurgitation, no effect was
observed on the putative underlying mechanism (prox-
imal extension of reflux episodes), which suggests that,
A
B
C
Figure 2 Mean (SD) number of daily occurrences of: (A) heartburn; (B)
regurgitation; and (C) heartburn and/or regurgitation, during the run-in
and at week 4 as reported in e-diaries. n = 28–31. Note that differences
in the changes from baseline to week 4 between placebo and
revexepride groups were not significant. SD, standard deviation; t.i.d.,
three times daily.
© 2014 The Authors.
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given the high data variability in this study, pH/
impedance assessment may not have been sensitive
enough to detect a difference in reflux events. Alter-
natively, the observed reduction in regurgitation
episodes may be attributable to a change in patients’
perception of these episodes. In support of such a mode
of action, the 5-HT4 receptor agonist tegaserod was
reported to decrease esophageal mechanosensitivity in
patients with functional heartburn.32
In addition to the pharmacodynamic endpoints, the
effect of revexepride 0.5 mg on reflux symptoms was
also evaluated through the use of a symptom e-diary
that was completed twice daily. There were no signif-
icant differences in treatment effects between the
revexepride 0.5 mg and placebo groups for any symp-
tom. This was consistent with the findings from the
HRQoL and symptom assessments (PAGI-QOL and
PAGI-SYM, respectively). These results are also con-
sistent with the findings of previous studies that have
demonstrated that other motility drugs such as the
5-HT4 receptor agonist cisapride in patients with
functional dyspepsia,29,33 and the reflux inhibitor
lesogaberan in patients with GERD who are partially
responsive to PPI therapy, have poor efficacy in
treating symptoms.34 Although lesogaberan showed a
significant effect on transient LES relaxations and
reflux variables, these findings did not translate into
meaningful symptom relief.
Table 2 Analysis of the changes from run-in to week 4 in the number of days with symptoms and percentage of days without symptoms as recorded
in patients’ e-diaries, using an ANCOVA model (pharmacodynamic population)
Week 4 results
LS mean change from run-in
Between-treatment difference
in LS means (95% CI) p-value
Revexepride 0.5 mg
t.i.d. (n = 31)
Placebo
(n = 29)
Number of days with symptoms
Heartburn
Night-time 1.361 0.834 0.527 (1.587 to 0.534) 0.323
Daytime 0.684 0.944 0.260 (0.678 to 1.198) 0.580
Daily 1.066 1.062 0.004 (1.072 to 1.063) 0.994
Regurgitation
Night-time 1.420 0.376 1.043 (2.285 to 0.198) 0.097
Daytime 0.904 0.648 0.256 (1.204 to 0.692) 0.589
Daily 1.039 0.882 0.156 (1.085 to 0.772) 0.736
Heartburn and/or regurgitation
Night-time 1.506 0.952 0.555 (1.759 to 0.649) 0.359
Daytime 0.446 0.878 0.432 (0.379 to 1.242) 0.289
Daily 0.573 0.837 0.264 (0.495 to 1.024) 0.487
Percentage of days without symptoms
Heartburn
Night-time 19.436 11.914 7.522 (7.622 to 22.666) 0.323
Daytime 9.777 13.490 3.712 (17.116 to 9.691) 0.580
Daily 15.233 15.172 0.060 (15.191 to 15.312) 0.994
Regurgitation
Night-time 20.279 5.374 14.905 (2.827 to 32.637) 0.097
Daytime 12.910 9.250 3.660 (9.887 to 17.206) 0.589
Daily 14.836 12.603 2.233 (11.028 to 15.494) 0.736
Heartburn and/or regurgitation
Night-time 21.521 13.593 7.928 (9.274 to 25.130) 0.359
Daytime 6.373 12.538 6.165 (17.746 to 5.416) 0.289
Daily 8.181 11.958 3.777 (14.628 to 7.075) 0.487
CI, confidence interval; LS, least-squares; t.i.d., three times daily.
Table 3 Summary of patients with TEAEs (safety population)
Revexepride 0.5 mg
t.i.d. (n = 34)
n (%)
Placebo
(n = 31)
n (%)
At least one TEAE 25 (73.5) 16 (51.6)
At least one serious TEAE 0 0
At least one severe TEAE 4 (11.8) 1 (3.2)
At least one TEAE that led to
investigational product
permanently discontinued
1 (2.9) 0
At least one TEAE
that led to death
0 0
At least one TEAE considered
treatment-related
19 (55.9) 9 (29.0)
TEAE severity
Mild 13 (38.2) 7 (22.6)
Moderate 8 (23.5) 8 (25.8)
Severe 4 (11.8) 1 (3.2)
If a patient had events of differing severity, the incidence of greatest
severity is presented. If a patient had more than one TEAE of the same
preferred term, the worst case was counted. TEAE, treatment-
emergent adverse event; t.i.d., three times daily.
© 2014 The Authors.
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Our findings do not necessarily negate a potential
benefit of treatment with revexepride 0.5 mg, particu-
larly when considering the efficacy of the drug in
accelerating gastric emptying in healthy volunteers
and animal models that has been shown in previous
trials (unpublished data). There are several potential
study limitations that may have contributed to the lack
of clear treatment effect. The relatively small number of
patients in this study is a crucial limiting factor. The
study was terminated without having reached the
initial target of 45 patients per treatment arm because
an interim analysis indicated that high variability in
reflux events and symptoms would require recruitment
of many more patients to demonstrate significant
differences between the treatment and placebo groups.
Despite attempts to reduce the variability in the pH/
impedance data through standardization and the use of a
central reader, statistical power remained an issue. Day-
to-day variability in the number of reflux events and
reflux-related symptomsmay genuinely be high, but the
picturemay also be complicated byhigh inter- and intra-
assessor variation in pH-impedance analyses.35
The lack of a clear treatment effect with revexepride
0.5 mg three times daily compared with placebo may
also reflect problems of identifying patients on acid-
suppressive therapies with reflux symptoms that are
related to persistent, weakly acidic reflux events or
dysmotility, who could potentially improve with a
prokinetic medication. An estimated 20% of patients
with reflux symptoms have functional heartburn36 and
this proportion is likely to be higher among those who
have a partial response to PPI therapy.17 In an attempt
to include patients with GERD in our study, partici-
pants were selected on the basis of the outcomes of 24-
h pH/impedance monitoring and were required to have
a minimum number of 25 liquid-containing reflux
events in a 24-h period, together with symptoms of
heartburn and/or regurgitation on at least 3 days a
week. A positive SAP was not an inclusion criterion in
this study. On one hand, this may have led to dilution
of the patient population with individuals who have
functional or non-reflux-related symptoms that are less
likely to respond to antireflux treatment, making the
detection of a significant treatment effect less proba-
ble.37 On the other hand, given the lack of beneficial
effects on reflux parameters, restricting inclusion to
patients with a positive SAP most likely would not
have changed the overall outcome of the study.
In the present trial, a relatively high proportion of
patients (16.9%) reported no response to PPI treatment
at baseline, which suggests that they might have had
esophageal dysmotility or functional heartburn rather
than GERD. In addition, benign physiological reflux
events may occur which are generally not associated
with pathological signs or symptoms.12 Therefore, the
persistent symptoms in the other 83.1% of patients
who did at least partially respond to PPI may have been
related to acid reflux or other pathology, such as
dysmotility or esophageal hypersensitivity. Esophageal
hypersensitivity is another factor contributing to per-
sistent symptoms, and prokinetic action seems less
likely to be effective for patients when this is a
prominent underlying pathophysiological factor.5 In
addition, approximately 15% of patients reported that
PPIs improved their symptoms ‘very much’ or ‘quite a
bit’; therefore, the potential positive effect of revexe-
pride on symptom improvement from baseline in these
patients may not have been as obvious if they had
reported that PPIs did not improve their symptoms
very much. The relatively low symptom severity
(indicated by PAGI-SYM scores) at baseline in both
placebo and revexepride treatment groups and poten-
tial psychosomatic effects may have also hampered the
ability to detect a significant treatment effect on
symptoms. Furthermore, the investigational dose of
0.5 mg and treatment duration (~26 days) might also
have been suboptimal.
Overall, and consistent with previous clinical stud-
ies, revexepride 0.5 mg was well-tolerated. Although
the number of AEs was higher than with placebo, most
TEAEs were mild or moderate, and no serious TEAEs
were observed. There were no clinically significant
safety findings; the safety evaluations did not raise any
concerns about the dose of revexepride administered in
this study. The problems of identifying patients with
GERD who have a partial response to PPIs in advance
of treatment and the limitations of questionnaires
targeting GERD parameters require further attention.
Future clinical studies of revexepride and other proki-
netics may be better directed at patients with symp-
toms that are clearly related to persistent weakly acidic
reflux, hypotensive esophageal dysmotility, or slow
gastric emptying (i.e., symptomatic dysfunction), as
determined by appropriate physiological tests.
In conclusion, pH/impedance monitoring and symp-
tom assessments did not reveal a consistent difference
in primary or secondary pharmacodynamic endpoints
between revexepride 0.5 mg three times daily and
placebo in this exploratory study. Overall, revexepride
0.5 mg was well-tolerated and no safety concerns were
identified.
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Additional supporting information may be found in the online version of this article at the publisher’s web site:
Figure S1. Analysis population flowchart. AE, adverse event; PD, pharmocodynamic; pH/impedance, combined
pH, and multichannel intraluminal impedance.
Table S1. Secondary endpoints: pH/impedance monitoring (pharmacodynamic population).
Table S2. Symptom association results reported by patients during pH/impedance monitoring (pharmacodynamic
population).
Table S3. Changes in symptom reflux association from baseline to day 28 for placebo and revexepride treatment
groups (pharmacodynamic population).
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